JL13 has clozapine-like actions on thermoregulatory cutaneous blood flow in rats: Involvement of serotonin 5-HT1A and 5-HT2A receptor mechanisms

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 34, Issue 1, 2010, Pages 136-142

  Capuano, B ^a   Crosby, I T ^a   McRobb, F M ^a   Taylor, D A ^a   Vom, A ^a   Blessing, W W ^b  

^a MONASH UNIVERSITY   (Australia)

^b FLINDERS UNIVERSITY   (Australia)

Author keywords

Alerting responses; Animal model; Atypical antipsychotic drugs; Dopamine; Schizophrenia

Indexed keywords

5 (4 METHYLPIPERAZIN 1 YL) 8 CHLOROPYRIDO[2,3 B][1,5]BENZOXAZEPINE; CLOZAPINE; DOPAMINE 2 RECEPTOR; JL 13; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NEUROLEPTIC AGENT; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SPIPERONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG STRUCTURE; NONHUMAN; RAT; SCHIZOPHRENIA; SKIN BLOOD FLOW; SYMPATHETIC INNERVATION; THERMOGENESIS; THERMOREGULATION; VASOCONSTRICTION; VASOMOTOR REFLEX;

ANIMALS; ARTERIES; BODY TEMPERATURE REGULATION; CLOZAPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; INJECTIONS, SUBCUTANEOUS; LASER-DOPPLER FLOWMETRY; OXAZEPINES; PIPERAZINES; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTOR, SEROTONIN, 5-HT2A; REGRESSION ANALYSIS; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; SKIN; VASOCONSTRICTION; VASOMOTOR SYSTEM;

EID: 73649084009     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2009.10.014     Document Type: Article

References (40)

1. Blessing W.W. Clozapine increases cutaneous blood flow and reduces sympathetic cutaneous vasomotor alerting responses (SCVARs) in rats: comparison with effects of haloperidol. Psychopharmacology (Berl) 181 (2005) 518-528
2. Blessing W.W., Zilm A., and Ootsuka Y. Clozapine reverses increased brown adipose tissue thermogenesis induced by 3, 4-methylenedioxymethamphetamine and by cold exposure in conscious rats. Neuroscience 141 (2006) 2067-2073
3. Blessing W.W., and Ootsuka Y. Activation of dopamine D2 receptors in the CNS inhibits sympathetic cutaneous vasomotor alerting responses (SCVARs), contributing to clozapine's SCVAR-inhibiting action. Prog Neuropsychopharmacol Biol Psychiatry 31 (2007) 328-336
4. Blessing W.W., and Seaman B. 5-hydroxytryptamine(2A) receptors regulate sympathetic nerves constricting the cutaneous vascular bed in rabbits and rats. Neuroscience 117 (2003) 939-948
5. Blessing W.W., Seaman B., Pedersen N.P., and Ootsuka Y. Clozapine reverses hyperthermia and sympathetically mediated cutaneous vasoconstriction induced by 3, 4-methylenedioxymethamphetamine (ecstasy) in rabbits and rats. J Neurosci 23 (2003) 6385-6391
6. Bleuler E. Dementia praecox or the group of schizophrenias (1950), International Universities Press, New York
7. Capuano B., Crosby I.T., Lloyd E.J., and Taylor D.A. Synthesis and preliminary pharmacological evaluation of 4′-arylmethyl analogues of clozapine. I. The effect of aromatic substituents. Aust J Chem 55 (2002) 565-576
8. Carlsson A. Mechanism of action of neuroleptic drugs. In: Lipton M.A., DiMascio A., and Killam K.F. (Eds). Psychopharmacology: a generation of progress (1978), Raven Press, New York 1057-1070
9. Chou Y.H., Halldin C., and Farde L. Occupancy of 5-HT1A receptors by clozapine in the primate brain: a PET study. Psychopharmacology (Berl) 166 (2003) 234-240
10. Courvoisier S., Fournel J., Ducrot R., Kolsky M., and Koetschet P. Pharmacodynamic properties of 3-chloro-10-(3-dimethylaminopropyl)-phenothiazine hydrochloride (R.P. 4560); experimental study of a new substance used in potentialized anesthesia and in artificial hibernation. Arch Int Pharmacodyn Ther 92 (1953) 305-361 (in French)
11. de Menezes R.C., Ootsuka Y., and Blessing W.W. Sympathetic cutaneous vasomotor alerting responses (SCVARs) are associated with hippocampal theta rhythm in non-moving conscious rats. Brain Res 1298 (2009) 123-130
12. Ellenbroek B.A., and Liégeois J.F. JL 13, an atypical antipsychotic: a preclinical review. CNS Drug Rev 9 (2003) 41-56
13. Ellenbroek B.A., Liégeois J.F., Bruhwyler J., and Cools A.R. Effects of JL13, a pyridobenzoxazepine with potential atypical antipsychotic activity, in animal models for schizophrenia. J Pharmacol Exp Ther 298 (2001) 386-391
14. Garcia J.N., Pedersen N.P., Nalivaiko E., and Blessing W.W. Tail artery blood flow measured by chronically implanted Doppler ultrasonic probes in unrestrained conscious rats. J Neurosci Methods 104 (2001) 209-213
15. Geyer M.A., Krebs-Thomson K., Braff D.L., and Swerdlow N.R. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl) 156 2-3 (2001) 117-154
16. Halford J.C., Harrold J.A., Boyland E.J., Lawton C.L., and Blundell J.E. Serotonergic drugs: effects on appetite expression and use for the treatment of obesity. Drugs 67 (2007) 27-55
17. Laborit H., and Huguenard P. Artificial hibernation by pharmacodynamical and physical means. Presse Med 59 (1951) 1329 (in French)
18. Leblanc J. Chlorpromazine hypothermia in rats. J Appl Physiol 13 (1958) 237-238
19. Liégeois J.F., Bruhwyler J., Damas J., Nguyen T.P., Chleide E.M., Mercier M.G., et al. New pyridobenzodiazepine derivatives as potential antipsychotics: synthesis and neurochemical study. J Med Chem 36 (1993) 2107-2114
20. Liégeois J.F., Bruhwyler J., Petit C., Damas J., Delarge J., Geczy J., et al. Oxidation sensitivity may be a useful tool for the detection of the hematotoxic potential of newly developed molecules: application to antipsychotic drugs. Arch Biochem Biophys 370 (1999) 126-137
21. Lopez-Munoz F., Alamo C., Cuenca E., Shen W.W., Clervoy P., and Rubio G. History of the discovery and clinical introduction of chlorpromazine. Ann Clin Psychiatry 17 (2005) 113-135
22. Meltzer H.Y. Mechanism of action of atypical antipsychotic drugs. In: Davis K.L., Charney D., Coyle J.T., and Nemeroff C. (Eds). Neuropsychopharmacology: the fifth generation of progress (2002), Lippincott Williams and Wilkins, Philadelphia 819-832
23. Meltzer H.Y., Li Z., Kaneda Y., and Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 27 (2003) 1159-1172
24. Meltzer H.Y., and Sumiyoshi T. Does stimulation of 5-HT(1A) receptors improve cognition in schizophrenia?. Behav Brain Res 195 (2008) 98-102
25. Nedergaard J., Bengtsson T., and Cannon B. Unexpected evidence for active brown adipose tissue in adult humans. Am J Physiol 293 (2007) E444-E452
26. Newcomer J.W. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry 68 Suppl 4 (2007) 8-13
27. Nichols D.E., Frescas S., Marona-Lewicka D., Huang X., Roth B.L., Gudelsky G.A., et al. 1-(2, 5-Dimethoxy-4-(trifluoromethyl)phenyl)-2-aminopropane: a potent serotonin 5-HT2A/2C agonist. J Med Chem 37 (1994) 4346-4351
28. Ootsuka Y., and Blessing W.W. Thermogenesis in brown adipose tissue: increase by 5-HT2A receptor activation and decrease by 5-HT1A receptor activation in conscious rats. Neurosci Lett 395 (2006) 170-174
29. Pedersen N.P., and Blessing W.W. Cutaneous vasoconstriction contributes to hyperthermia induced by 3, 4-methylenedioxymethamphetamine (ecstasy) in conscious rabbits. J Neurosci 21 (2001) 8648-8654
30. Saito M.Y., Okamatsu-Ogura Y., Matsushita M., Watanabe K., Yoneshiro T., Nio-Kobayashi J., et al. High incidence of metabolically active brown adipose tissue in healthy adult humans: effects of cold exposure and adiposity. Diabetes 58 (2009) 1526-1531
31. Shiloh R., Schapir L., Bar-Ziv D., Stryjer R., Konas S., Louis R., et al. Association between corneal temperature and mental status of treatment-resistant schizophrenia inpatients. Eur Neuropsychopharmacol 19 (2009) 654-658
32. Stefanidis A., Verty A.N., Allen A.M., Owens N.C., Cowley M.A., and Oldfield B.J. The role of thermogenesis in antipsychotic drug-induced weight gain. Obesity (Silver Spring) 17 (2009) 16-24
33. Tauscher J., Hussain T., Agid O., Verhoeff N.P., Wilson A.A., Houle S., et al. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics. Am J Psychiatry 161 (2004) 1620-1625
34. Taylor D.P. Serotonin agents in anxiety. Ann N Y Acad Sci 600 (1990) 545-556
35. van den Buuse M., and Gogos A. Differential effects of antipsychotic drugs on serotonin-1A receptor-mediated disruption of prepulse inhibition. J Pharmacol Exp Ther 320 3 (2007) 1224-1236
36. Trichard C., Paillere-Martinot M.L., Attar-Levy D., Recassens C., Monnet F., and Martinot J.L. Binding of antipsychotic drugs to cortical 5-HT2A receptors: a PET study of chlorpromazine, clozapine, and amisulpride in schizophrenic patients. Am J Psychiatry 155 (1998) 505-508
37. Vanina Y., Podolskaya A., Sedky K., Shahab H., Siddiqui A., Munshi F., et al. Body weight changes associated with psychopharmacology. Psychiatr Serv 53 (2002) 842-847
38. van Marken Lichtenbelt W.D., Vanhommerig J.W., Smulders N.M., Drossaerts J.M., Kemerink G.J., Bouvy N.D., et al. Cold-activated brown adipose tissue in healthy men. N Engl J Med 360 (2009) 1500-1508
39. Yasuno F., Suhara T., Ichimiya T., Takano A., Ando T., and Okubo Y. Decreased 5-HT1A receptor binding in amygdala of schizophrenia. Biol Psychiatry 55 (2004) 439-444
40. Zethof T.J., Van der Heyden J.A., Tolboom J.T., and Olivier B. Stress-induced hyperthermia as a putative anxiety model. Eur J Pharmacol 294 (1995) 125-135